Lead Product(s): Imatinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AER-901
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Hangzhou Chance Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2021
Aerami will undertake its own PAH clinical development program in the US and other territories for AER-901, drug device combination product pursuant to a worldwide license from Vectura Group plc to develop and commercialize imatinib for the treatment of PAH.